Cerner Corp (NASDAQ: CERN) was upgraded by equities research analysts at Raymond James (NYSE: RJF) from a “market perform” rating to an “outperform” rating in a research note issued to investors on Monday.
CERN has been the subject of a number of other recent research reports. Analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Cerner Corp from $74.00 to $79.00 in a research note to investors on Friday. They now have an “equal weight” rating on the stock. Separately, analysts at UBS AG (NYSE: UBS) reiterated a “neutral” rating on shares of Cerner Corp in a research note to investors on Friday, March 23rd. Finally, analysts at UBS AG (NYSE: UBS) raised their price target on shares of Cerner Corp from $68.00 to $80.00 in a research note to investors on Friday, March 23rd. They now have a “buy” rating on the stock.
Cerner Corp traded up 0.17% on Monday, hitting $81.25. Cerner Corp has a 52-week low of $53.93 and a 52-week high of $81.48. The company has a market cap of $13.850 billion and a price-to-earnings ratio of 42.69.
The company last announced its quarterly results on Thursday, April 26th. It reported $0.54 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.50 EPS by $0.04. The company’s quarterly revenue was up 30.4% on a year-over-year basis. Analysts expect that Cerner Corp will post $0.59 EPS next quarter.
Cerner Corporation (Cerner) is a supplier of healthcare information technology (HIT) solutions, healthcare devices and related services.